Montenegro is exploring domestic production of selected medicines through state-owned pharmaceutical distributor Montefarm, a move that could reduce some supply risks but would require investment in manufacturing standards, quality control and regulatory capacity.
The government said on Sept. 2 that pharmaceutical production was discussed during talks with senior representatives of Türkiye’s health ministry and international healthcare organisation USHAŞ.
Foreign Minister Ervin Ibrahimović told the Turkish delegation that Montefarm planned to start producing certain types of medicines and invited Turkish companies to consider cooperation and investment. No investment value, product list, partner or production timetable has been announced.
The proposal would represent a significant extension of Montefarm’s traditional role.
The state institution procures and distributes medicines and medical supplies to Montenegro’s public health system and operates 55 pharmacies across the country. It has also maintained a dedicated Galenic Laboratory Sector since 2021 to prepare the documentation, quality standards and regulatory requirements needed to establish production of galenic medicines.
That existing project makes small-scale pharmaceutical preparation a more realistic starting point than building a conventional drug-manufacturing industry from scratch.
Galenic production typically involves medicines prepared in larger batches within authorised pharmacy or healthcare structures using established formulations. For a market the size of Montenegro, such products could offer a way to manufacture selected medicines for public institutions without attempting to compete immediately with large European or Asian generic-drug producers.
The economics become harder as manufacturing complexity increases.
Montenegro has a population of little more than 600,000, meaning domestic demand for most individual medicines is limited. Pharmaceutical factories depend on high utilisation because manufacturing lines, laboratories, quality systems and regulatory staff impose substantial fixed costs.
A facility producing only for Montenegro would therefore have to focus on products where security of supply, short production runs or public-health needs justify local manufacturing.
Commodity generic medicines produced at very large scale internationally would be more difficult to manufacture competitively unless a Montenegrin facility could also supply export markets.
The regulatory barrier is similarly high.
Montenegro’s medicines framework regulates industrial manufacture and requires systems to guarantee quality, safety and efficacy. The national medicines agency, CInMED, maintains registers of manufacturers and in 2026 updated its procedures for manufacturing authorisations and Good Manufacturing Practice, or GMP, certification.
Any move beyond relatively limited galenic production would therefore require considerably more than production equipment.
Manufacturers need controlled premises, qualified personnel, validated manufacturing processes, analytical laboratories, documented quality systems, batch release procedures and mechanisms for investigating deviations and product complaints.
Raw-material suppliers also have to be controlled.
For sterile products, the technical and investment requirements rise further because contamination control becomes critical.
That suggests Montenegro’s first domestic manufacturing programme would be more likely to concentrate on technically manageable products rather than complex biologics, vaccines or advanced sterile medicines.
Türkiye could be relevant precisely because it possesses a much larger pharmaceutical manufacturing base.
A Turkish partner could potentially supply equipment, production know-how, validated formulations or staff training while Montefarm provides local market knowledge and access to Montenegro’s public healthcare supply chain.
The Sept. 2 discussions remain preliminary, however, and the government has not said that any Turkish company has committed to invest.
The main strategic argument for local manufacturing is likely to be supply security rather than import substitution alone.
Small pharmaceutical markets can be vulnerable when manufacturers prioritise larger countries during shortages or decide that maintaining registrations for low-volume products is commercially unattractive.
A domestic facility cannot eliminate that exposure because active pharmaceutical ingredients and many other inputs would still need to be imported.
It could nevertheless give Montenegro greater control over selected products that are repeatedly difficult to procure or where short production runs are commercially unattractive to international suppliers.
Montefarm’s role could provide another advantage: an anchor customer already exists.
The institution supplies pharmacies, health centres, hospitals, the Clinical Centre, the Institute of Public Health and other public institutions.
Predictable public-sector demand could make some production lines easier to justify financially than a purely commercial factory dependent on retail sales.
But that structure also creates governance questions.
A state entity that both procures medicines and manufactures some of them would need clear rules separating production economics from purchasing decisions. Public tenders would still need to preserve competition and demonstrate that domestically produced medicines offer appropriate quality and value.
Otherwise, supply-security policy could become an expensive form of protected manufacturing.
The larger commercial opportunity may therefore lie in building a pharmaceutical-services ecosystem around a relatively modest production base.
Montenegro would need pharmacists specialising in production, analytical chemists, microbiologists, quality-assurance personnel, validation engineers and regulatory specialists.
Independent laboratories could gain work from raw-material and finished-product testing.
Engineering companies could provide controlled environments, ventilation, purified-water systems and monitoring equipment.
Software providers could supply batch documentation, inventory control and quality-management systems.
Those functions are valuable regardless of whether Montenegro ultimately produces dozens of medicines or only a small strategic portfolio.
The project could also strengthen the country’s broader healthcare resilience.
A functioning pharmaceutical production and testing capability provides expertise that can be used during shortages, emergency procurement or disruptions to regional supply chains.
The lessons of the COVID-19 period made many small European countries more aware of dependence on distant manufacturing centres.
Montenegro’s challenge is to avoid responding by attempting to manufacture everything domestically.
Its scale argues for selective production.
The strongest business case would probably involve medicines where local preparation solves a specific supply problem, where production technology is manageable and where public-sector demand is sufficiently predictable to support the fixed cost.
The planned Galenic Laboratory provides a logical testing ground.
If Montefarm can establish compliant production, demonstrate stable quality and show that costs compare favourably with imported alternatives, additional product categories could follow.
If the economics do not work at that level, a much larger industrial pharmaceutical project would be even harder to justify.
The latest Turkish talks therefore do not yet amount to the creation of a Montenegrin pharmaceutical industry.
They do, however, signal a potentially important change in strategy.
Montefarm has traditionally been the organisation that buys and distributes medicines manufactured elsewhere.
Montenegro is now asking whether, for a carefully selected part of that supply chain, it should also learn how to make them.
